Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875597 | 0.92 | MAPT (0.44) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL16843012 | 0.89 | MAPT (0.40) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL17703321 | 0.88 | VDR (0.53) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL20752387 | 0.85 | VDR (0.53) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL17703322 | 0.84 | MAPT (0.41) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL17878819 | 0.82 | VDR (0.47) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL15908156 | 0.81 | MAPT (0.40) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL21277821 | 0.80 | MAPT (0.35) | MAPTVDRGAASMN1; SMN2RIPK1 | |
| SCHEMBL17703318 | 0.80 | VDR (0.53) | MAPTALDH1A1VDRGAASMN1; SMN2 | |
| SCHEMBL17703319 | 0.80 | VDR (0.53) | MAPTALDH1A1VDRGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133556-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC INDUSTRIES INC | 2023-05-04 | — | — | US | disclosed |
| US-20230133556-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC INDUSTRIES INC | 2023-05-04 | — | — | US | disclosed |
| US-11566106-B2 | Composite materials containing benzoxazines and method for making the same | CYTEC INDUSTRIES INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20200291179-A1 | COMPOSITE MATERIALS CONTAINING BENZOXAZINES AND METHOD FOR MAKING THE SAME | CYTEC INDUSTRIES INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3240829-B1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC IND INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2016109399-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC INDUSTRIES INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185908-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC INDUSTRIES INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185908-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | CYTEC INDUSTRIES INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291179-A1 | COMPOSITE MATERIALS CONTAINING BENZOXAZINES AND METHOD FOR MAKING THE SAME | F12, COL1A1, BRIX1 | MAPT 2756/4885ALDH1A1 1216/4885VDR 1918/4885 |
| US-11566106-B2 | Composite materials containing benzoxazines and method for making the same | F12, COL1A1, BRIX1 | MAPT 2756/4885ALDH1A1 1216/4885VDR 1918/4885 |
| US-20230133556-A1 | BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME | F12, BRIX1, COL1A1 | MAPT 2194/4885ALDH1A1 1160/4885VDR 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.